Growth hormone deficiency and growth-hormone secretagogue pharmacology — compounds assessed
The 10 compounds the Institute assesses in growth hormone deficiency and growth-hormone secretagogue pharmacology.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
Growth-hormone secretagogue, ghrelin receptor agonist (hexapeptide)1 contributing trialfull monograph
A peak growth hormone below 16 ng/mL after 100 µg intravenously supports severe adult growth-hormone deficiency in the approved Japanese diagnostic criteria — The diagnostic evidence base is adequate and the compound holds a marketing authorisation for it…
Moderate -
A luteinising hormone rise after gonadorelin distinguishes pituitary from hypothalamic causes of hypogonadotropic hypogonadism — The diagnostic evidence base is established and underpins the marketing authorisations.
Moderate -
Peak stimulated growth hormone response used diagnostically; a peak below 5 µg/L after sermorelin supports pituitary rather than hypothalamic origin of deficiency — The evidence base supports a diagnostic application. The Institute found no adequately powered…
Moderate -
IGF-1 rose by a mean of 81 ng/mL, with 34 % of participants exceeding the upper limit of normal at some point — IGF-1 monitoring is required; the proportion exceeding the reference range is the reason.
Moderate -
Growth-hormone-releasing hormone analogue with albumin-binding drug affinity complex2 contributing trialsfull monograph
Mean IGF-1 increased 1.5- to 3.0-fold above baseline and remained elevated for 6 to 11 days after a single dose in a phase 1 study of 11 participants — A genuine phase 1 pharmacodynamic result exists and the Institute reports it. It establishes that the…
Low -
Growth-hormone secretagogue, non-selective ghrelin receptor agonist (hexapeptide)1 contributing trialfull monograph
Dose-dependent acute growth-hormone release with attenuation on repeated administration — Historical human pharmacodynamic data exist. No therapeutic outcome trial does.
Low -
Growth-hormone secretagogue, non-selective ghrelin receptor agonist (hexapeptide)2 contributing trialsfull monograph
Marked acute growth-hormone release; the response attenuates substantially over 8 to 16 weeks of continuous administration — Tachyphylaxis is the defining clinical limitation and is documented in the historical literature.
Low -
Growth-hormone secretagogue, selective ghrelin receptor agonist (pentapeptide)2 contributing trialsfull monograph
Dose-dependent growth-hormone release demonstrated in preclinical models and in early human study — The preclinical pharmacology is well characterised. Human data are limited to early-phase work.
Low -
No randomised human evidence identified for this analogue — No trial of LR3 IGF-1 in any human population was located.
Not rated -
Diagnostic use as a probe of hypothalamic-pituitary-gonadal function — The diagnostic application is the best-established use.
Not rated
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 1998;139(5):552–561. doi:10.1530/eje.0.1390552 · PMID 9849822
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.